Showing 321 - 340 results of 25,281 for search '(( 5 ((non decrease) OR (nn decrease)) ) OR ( 50 ((mg decrease) OR (a decrease)) ))', query time: 0.66s Refine Results
  1. 321

    Table_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.docx by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  2. 322
  3. 323
  4. 324
  5. 325
  6. 326

    FTY720 decreased viability, proliferation, and motility and induced apoptosis in human hepatoblastoma cells. by Laura L. Stafman (6577184)

    Published 2019
    “…<p>(A) Following 24 hours of treatment with FTY720, the viability of HuH6 cells measured using the alamarBlue cell viability assay was significantly decreased (LD<sub>50</sub> = 8.4 μM, p ≤ 0.05). …”
  7. 327
  8. 328

    Non-Steady-State Fickian Diffusion Models Decrease the Estimated Gel Layer Diffusion Coefficient Uncertainty for Diffusive Gradients in Thin-Films Passive Samplers by Samuel D. Hodges (16412358)

    Published 2023
    “…A finite difference model (FDM) developed based on Fick’s second law with non-steady-state (N-SS) flux decreased uncertainty in <i>D</i><sub>Gel</sub> tenfold. …”
  9. 329
  10. 330

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin... by Chanel Avenant (409756)

    Published 2025
    “…Both contraceptives substantially decreased, from D0 to 25W, the total testosterone [DMPA-IM D0 0.560, 25W 0.423 nmol/L, -24.3% (p < 0.0001); NET-EN D0 0.551, 25W 0.253 nmol/L, -54.1%, (p < 0.0001)], SHBG [DMPA-IM D0 45.0, 25W 32.7 nmol/L, -29.8% (p < 0.0001); NET-EN D0 50.2, 25W 17.6 nmol/L, -65.1% (p < 0.0001)], and calculated free testosterone levels [DMPA-IM D0 6.87, 25W 5.38 pmol/L, -17.2% (p = 0.0371); NET-EN D0 6.00, 25W 3.70, -40.0% (p < 0.0001)]. …”
  11. 331

    Fig 3 - by Yan Shu (441370)

    Published 2022
  12. 332

    Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

    Published 2025
    “…(a) and (b): Average negative predictive value for and , respectively for and . …”
  13. 333
  14. 334

    DataSheet_1_Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2.pdf by Yun Ji (464484)

    Published 2022
    “…Here we describe two fully human mAbs, amubarvimab (BRII-196) and romlusevimab (BRII-198) that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein and effectively neutralize SARS-CoV-2 variants. …”
  15. 335

    <i>Bbs1</i><sup><i>M390R/M390R</i></sup> mice have decreased hippocampal proliferation. by Thomas K. Pak (10686881)

    Published 2021
    “…At P30, mice were started on BrdU injections (2x50mg/kg) for five days. At P44, mice were taken down. …”
  16. 336
  17. 337
  18. 338
  19. 339
  20. 340

    Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

    Published 2025
    “…EC<sub>50</sub> estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC<sub>0−3d</sub> of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”